


PHARMACEUTICAL 2020

OMEROS CORP Rank 203 of 358







PHARMACEUTICAL 2020

OMEROS CORP Rank 203 of 358



The relative strengths and weaknesses of OMEROS CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of OMEROS CORP compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 77% points. The greatest weakness of OMEROS CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 60% points.

The company's Economic Capital Ratio, given in the ranking table, is 58%, being 22% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	103,745
Cost of Goods Sold	865
Intangible Assets	0
Liabilities, Current	55,459
Liabilities, Non-Current	0
Other Assets	29,395
Other Compr. Net Income	0
Other Expenses	22,657
Other Liabilities	0
Other Net Income	1,553
Other Revenues	111,805
Property and Equipment	3,829
Research and Development	109,696
Selling, General and Administrative Expense	64,626

Output Variable	Value in 1000 USD
Assets	136,969
Liabilities	55,459
Expenses	197,844
Revenues	111,805
Stockholders Equity	81,510
Net Income	-84,486
Comprehensive Net Income	-84,486
Economic Capital Ratio	58%

